AI summary by TwinMind

23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech

Sequoia Capital

38m 15s

Company Foundation and Early Vision (2006)

  • Anne Wojcicki co-founded 23andMe in 2006 to revolutionize healthcare industry
  • First company to offer direct affordable access to genome information
  • Mission: help people access, understand, and benefit from human genome
  • Background: Wojcicki spent 10 years investing in healthcare companies
    • Realized healthcare system optimized to monetize patients rather than serve them
    • Patients lacked voice in their own healthcare decisions
  • Timing advantage: human genome 92% sequenced, costs declining rapidly
  • Vision: create community focused on people's interests vs. corporate bottom lines

Groundbreaking Product Launch and Market Discovery

  • Initial launch features:
    • Democratized genome access (previously cost $1M+ for individuals)
    • Provided information medical community wouldn't return (e.g., Alzheimer's risk)
    • Parkinson's testing driven by Sergey Brin's personal interest
    • Created consented database for relative finder and ancestry composition
  • Launch success: New York Times cover story, Wired cover, Fashion Week party
  • Pricing evolution:
    • Started at $1,000 price point
    • Sold 1,000 kits first day, then dropped to 15-20 kits/day
    • Cut price to $99, sold 17,000-18,000 kits in one day
    • Exhausted entire inventory in single day
  • Raised Series C funding based on demand data

Medical Establishment Resistance

  • Heavy discrediting from medical profession in early days
  • Medical meetings refused 23andMe attendance due to direct-to-consumer model
  • Physician walked out of dinner, predicted "destruction in people's lives" due to non-paternity rates
  • Fear about genetics information and consumer behavior without physician supervision
  • Concerns unsubstantiated by data

FDA Regulatory Crisis (November 2013)

  • FDA ordered 23andMe to shut down all health testing services
  • Warning letter became public days later
  • David Kessler (former FDA commissioner) warned Wojcicki about letter's seriousness
  • Three response options considered:
    • Fold company (rejected immediately)
    • Fight FDA (customer support existed)
    • Full compliance (chosen path)
  • Regulatory leader advised: "Put your head down and do the work... slow and painful... years"

Regulatory Compliance Journey (2014-2015)

  • Hired Cathy Hibbs as Chief Legal and Regulatory Officer (April 2014)
  • Major transition from unregulated to regulated company
  • FDA requirements:
    • Prove report accuracy through technical challenges
    • Demonstrate consumer comprehension through testing
  • Two years of meticulous testing and data provision
  • FDA authorization received in 2015
  • Standing ovation for regulatory team achievement
  • Competitive advantage: only company with FDA-approved tests

Business Growth During Regulatory Period

  • Ancestry product sales accelerated 2014-2015
  • Reached scale of 100,000+ people, approaching 1 million
  • Became largest consented genetic database in world
  • Database size enabled interesting research opportunities

Therapeutics Division Launch (2015)

  • Wojcicki's original vision: use human genetic data for drug discovery
  • Drugs with genomic foundation 2-3x more likely to succeed
  • Hired Richard Scheller (retired Genentech executive) as head of Therapeutics
  • Built laboratory from scratch:
    • No existing lab facilities (closest was kitchen)
    • Bought used equipment from company auctions
    • Hired talented team, moved to laboratory space
  • Focused on antibody therapeutics as more straightforward approach
  • Identified multiple drug targets worth pursuing
  • GSK collaboration: 50+ programs identified
  • Database grew to 12-14 million people (largest in world)

Peak Brand Awareness and Market Saturation (2018-2019)

  • 2018: Incredible inflection point, kit sales took off
  • Brand awareness hit all-time high:
    • Lizzo dressed as 23andMe for Halloween
    • Eddie Murphy discussed 23andMe on Saturday Night Live
    • Featured in crossword puzzles and jokes
  • 2019: Sales started to flatline
  • Contributing factors:
    • Privacy concerns (Cambridge Analytica, Golden State Killer)
    • Increased competition from Ancestry.com
    • Company focused on health while ancestry market grew
    • Insufficient marketing investment during growth period

Business Pivot and Workforce Reduction (2019)

  • Laid off 100 people (14% of workforce)
  • Readjusted marketing budgets and spend
  • Emphasized choice and transparency principles
  • Pivoted from information provider to full-stack healthcare solution
  • Subscription model with ongoing updates on genetic information

Telehealth Expansion (2020-2021)

  • Initially skeptical about telemedicine feasibility (2019 offsite)
  • COVID-19 pandemic accelerated telemedicine acceptance
  • Acquired Lemonade Health (closed November 2021):
    • Clinicians licensed in all 50 states
    • Online pharmacy capabilities
    • Pharmacogenomics opportunities (medication optimization based on genome)
  • Still harmonizing acquisition and bringing services together

Current Drug Development Success

  • June 1, 2023: Announced 23ME-610 investigational cancer drug
  • First-of-its-kind antibody for advanced cancers
  • Moving into Phase 2 testing:
    • Phase 1: Demonstrated safety and tolerability
    • Phase 2: Testing efficacy in patients
  • Long development road ahead but significant milestone

Medical Community Transformation

  • Survey results: 90%+ of physicians understand genetics' clinical value
  • Massive transformation in medical acceptance
  • Team endured continuous proof of information accuracy and safety
  • Slowly won over medical world through persistent data-driven approach

Future Vision and Leadership Philosophy

  • Goal: World's only leader in genomic-based medicine
  • Personalized prevention focus:
    • Customized screening schedules (colonoscopy, mammograms)
    • Genetic-specific recommendations (e.g., fava bean toxicity)
    • Keeping people healthy vs. treating illness
  • Crucible moments as innovation opportunities
  • Brand risk-taking philosophy: "Why else have a brand if you don't want to take risks?"
  • Leadership focus on inspiration and vision maintenance

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome